Expertise in
10
conditions

Dr. Brook A. Saunders

Oncology
Thompson Cancer Survival Center
1915 White Ave, 
Knoxville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
Thompson Cancer Survival Center
1915 White Ave, 
Knoxville, TN 

Overview

Brook Saunders is an Oncologist practicing medicine in Knoxville, Tennessee.

Dr. Saunders is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Malignant Mixed Mullerian Tumor.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 5 clinical trials. Dr. Saunders is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in TN

Hospital Affiliations

Fort Loudoun Medical Center
Fort Sanders Regional Medical Center
Roane Medical Center
Leconte Medical Center
Parkwest Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Thompson Cancer Survival Center
1915 White Ave, Knoxville, TN 37916
Other Locations
The Thompson Cancer Survival Center
9711 Sherrill Blvd, Knoxville, TN 37932

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials

2 Total Publications

Ovarian cyst fluids are a cache of tumor biomarkers that include calgranulin A and calgranulin B isoforms.
Ovarian cyst fluids are a cache of tumor biomarkers that include calgranulin A and calgranulin B isoforms.
Journal: Cancer investigation
Published: August 07, 2013
Similar Doctors
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Expertise in
26
conditions
Dr. Haydar A. Frangoul
Hematology | Oncology
Referral may be required

TriStar Medical Group Children's Specialists - West Clinch Ave

2018 Clinch Ave, 
Knoxville, TN 
 (0.1 miles away)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Haydar Frangoul is a Hematologist and an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Frangoul is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Frangoul is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Office

1928 Alcoa Hwy Ste 127, 
Knoxville, TN 
 (5.0 miles away)
865-305-8787
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Larry Kilgore is an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Kilgore is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Desmoplastic Small Round Cell Tumor, Ovarian Cancer, Ovarian Carcinosarcoma, and Ureteroscopy. Dr. Kilgore is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

University Of Tennessee Medical Center

1924 Alcoa Hwy, 
Knoxville, TN 
 (1.2 miles away)
865-305-6740
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kristopher Kimball is an Oncologist practicing medicine in Knoxville, Tennessee. Dr. Kimball is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Bladder Reconstruction. Dr. Kimball is currently accepting new patients.

Frequently Asked Questions about Dr. Brook A. Saunders

How do I make an appointment with Dr. Brook A. Saunders?

You can book an appointment with Dr. Brook A. Saunders by calling their office at 865-331-1720. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Brook A. Saunders a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Brook A. Saunders is classified as an Distinguished expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Brook A. Saunders specialize in?

While Dr. Brook A. Saunders is a Oncology, they have specific expertise in Endometrial Cancer, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Brook A. Saunders participate in research or clinical trials?

Yes. Dr. Brook A. Saunders has published 2 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Brook A. Saunders's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Brook A. Saunders accept my insurance?

Dr. Brook A. Saunders accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 865-331-1720 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Saunders's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile